Skip to main content Skip to footer

Algernon Pharmaceuticals Inc.

  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Pipeline
    • Overview
    • NP-120 (Ifenprodil)
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Jun 06, 2023 7:00am EDT

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Jun 05, 2023 7:00am EDT

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

May 31, 2023 7:19am EDT

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

May 05, 2023 5:00pm EDT

Algernon Pharmaceuticals Announces Closing of Rights Offering

Apr 20, 2023 7:00am EDT

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

Apr 17, 2023 7:00am EDT

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Apr 04, 2023 7:00am EDT

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Apr 03, 2023 7:00am EDT

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

Mar 21, 2023 7:00am EDT

Algernon Pharmaceuticals Announces Launch of Rights Offering

Mar 02, 2023 8:00am EST

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2023 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap